Key result
CD36 inhibition emerges as a promising therapeutic target to curb vascular injury in ischemic stroke.
Answers are grounded in this paper and cite their sources.
This review highlights the class B scavenger receptor CD36 as a central mediator of vascular inflammation, oxidative stress, and impaired angiogenesis in comorbidities such as hyperlipidemia and diabetes, supporting CD36 antagonism as a potential therapeutic target for ischemic stroke.
Stroke pathology involves multifactorial pro-death responses, including inflammation, oxidative stress, vascular dysfunction, and activation of necrotic and apoptotic pathways. The interruption of a single specific pathway in defined stroke model systems has not been sufficient to address the multifactorial nature of stroke-induced injuries in the human population. CD36 is a class B scavenger receptor that functions in regulating normal physiological and pathological functions. CD36 pathways are activated by several distinct ligands. Convergence of these pathways results in inflammatory responses and endothelial dysfunction, which may be an underlying cause of cardio- and cerebrovascular diseases. The current review describes receptor CD36-ligand interactions relevant to endothelial function and discusses how targeting CD36 may have therapeutic utility in stroke.
No takes yet. Share an insight, caveat, or question.
Sunghee Cho (2012) conducted a review in Ischemic stroke and cerebrovascular endothelial dysfunction. CD36 inhibition / pharmacological antagonism (e.g., hexarelin, EP80317, salvianolic acid B, statins, ursolic acid, SS31 peptide) was evaluated. CD36 activation by diverse ligands promotes vascular inflammation, oxidative stress, and anti-angiogenic responses, making CD36 inhibition a promising therapeutic strategy in ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: